Fundamental Analysis of BLUEBIRD BIO INC(NASDAQ:BLUE) stock

Fundamental Rating

Taking everything into account, BLUE scores 1 out of 10 in our fundamental rating. BLUE was compared to 568 industry peers in the Biotechnology industry. BLUE may be in some trouble as it scores bad on both profitability and health. BLUE is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

BLUE had negative earnings in the past year.

BLUE had a negative operating cash flow in the past year.

BLUE had negative earnings in each of the past 5 years.

In the past 5 years BLUE always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -64.62%, BLUE is not doing good in the industry: 62.12% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-64.62%
ROE	N/A
ROIC	N/A

ROA(3y)-73.42%

ROA(5y)-60.14%

ROE(3y)-154.55%

ROE(5y)-114.15%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BLUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for BLUE has been increased compared to 1 year ago.

BLUE has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, BLUE has a worse debt to assets ratio.

2.2 Solvency

BLUE has an Altman-Z score of -13.73. This is a bad value and indicates that BLUE is not financially healthy and even has some risk of bankruptcy.

BLUE has a Altman-Z score of -13.73. This is amonst the worse of the industry: BLUE underperforms 80.35% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-13.73

ROIC/WACCN/A

WACC11.71%

2.3 Liquidity

A Current Ratio of 0.51 indicates that BLUE may have some problems paying its short term obligations.

BLUE's Current ratio of 0.51 is on the low side compared to the rest of the industry. BLUE is outperformed by 92.92% of its industry peers.

BLUE has a Quick Ratio of 0.51. This is a bad value and indicates that BLUE is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.33, BLUE is not doing good in the industry: 94.51% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.51
Quick Ratio	0.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BLUE have decreased strongly by -148.91% in the last year.

BLUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 143.67%.

BLUE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.58% yearly.

EPS 1Y (TTM)-148.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%53.03%

Revenue 1Y (TTM)143.67%

Revenue growth 3YN/A

Revenue growth 5Y-11.58%

Sales Q2Q%-14.36%

3.2 Future

Based on estimates for the next years, BLUE will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.13% on average per year.

Based on estimates for the next years, BLUE will show a very strong growth in Revenue. The Revenue will grow by 65.17% on average per year.

EPS Next Y19.82%

EPS Next 2Y27.69%

EPS Next 3Y18.11%

EPS Next 5Y14.13%

Revenue Next Year85.92%

Revenue Next 2Y144.53%

Revenue Next 3Y93.52%

Revenue Next 5Y65.17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLUE. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLUE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BLUE's earnings are expected to grow with 18.11% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y27.69%

EPS Next 3Y18.11%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BLUE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BLUEBIRD BIO INC

NASDAQ:BLUE (12/18/2024, 11:44:33 AM)

8.97

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.74B

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-64.62%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.51
Quick Ratio	0.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-148.91%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y19.82%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)143.67%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BLUEBIRD BIO INC (BLUE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens